BrainStorm Cell Therapeutics Inc. (BCLI) Reaches New 52-Week High at $3.87
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s share price reached a new 52-week high on Friday . The stock traded as high as $3.87 and last traded at $3.14, with a volume of 3,094,755 shares traded. The stock had previously closed at $3.56.
Separately, Maxim Group reissued a “buy” rating and issued a $5.00 price target on shares of BrainStorm Cell Therapeutics in a research note on Wednesday, May 11th.
The firm has a 50-day moving average of $2.46 and a 200-day moving average of $2.42. The firm’s market cap is $58.39 million.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.15. On average, analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.58) EPS for the current year.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.